At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 673 enrolled
Drug / intervention
Bexagliflozin +1 moredrug
Likely dose
Bexagliflozin 20 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Integrated Assessment of the Safety and Effectiveness of Bexagliflozin Tablets, 20 mg, for the Management of Essential Hypertension
In Brief
A Phase 3 clinical trial evaluating Bexagliflozin and Placebo for Essential Hypertension. Completed, enrolled 673 participants across 87 sites.
Detailed Summary
This integrated assessment consists of two studies, 603A and 603B, to be carried out sequentially in a common study population. Participating subjects informed of the trial design and their consent to participate in both studies were to be obtained in a single consent form. Approximately 680 male or female adult subjects were to be enrolled.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEssential Hypertension
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
201820192020202120222023202420252026
Enrollment StartOct 2017
First PostedMay 2018
Primary CompletionNov 2018
TodayJul 2026
First PostedMay 2, 2018
Enrollment StartOct 18, 2017
Primary CompletionNov 30, 2018
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 8.2 years ago
Interventions
Bexagliflozindrug
Bexagliflozin tablet, 20 mg
Placebodrug
Placebo (inactive) tablet to match the active drug